David S. Shames

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al. · New England Journal of Medicine · 2018 · 3.3K citations · Full text

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R. Gandara, Sarah Paul, Marcin Kowanetz et al. · Nature Medicine · 2018 · 1.2K citations

Oncology, Pathology, Bronchial Neoplasm +5

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

Charles M. Rudin, Steffen Durinck, Eric Stawiski et al. · Nature Genetics · 2012 · 1.1K citations

Medicine, Pathology, Cancer Genomics +8

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

Carl M. Gay, C. Allison Stewart, Elizabeth M. Park et al. · Cancer Cell · 2021 · 864 citations · Full text

Immunogenetics, Systems Biology, Distinct Therapeutic Vulnerabilities +11

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah et al. · Nature · 2021 · 578 citations

Adjuvant Immunotherapy, Cancer Immunosurveillance, Urology +1